Targeting the pathobiology of neutrophil extracellular traps

Citryll – a dutch biotech company – is taking a new approach to treat autoimmune and other human diseases like lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis and organ damage due to sepsis, by targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation or acquired immunity.

Scientific Approach

Citryll targets Neutrophil Extracellular Traps (NET) formation with a human antibody CIT-013 that interferes with the formation of NETs as well as promotes the clearance of NETs. A range of human diseases with potential for SLE, RA, vasculitis, asthma, IPF and other indications can be treated with CIT-013.

CIT-013 Development

A first human dosing will be done in 2021 as part of a Single Ascending Dose (SAD) study in healthy volunteers. GMP production and formulation of the antibody is being carried out by Citryll’s CMC partner Lonza and CTA enabling studies are being finalised in 2020.

Jobs at Citryll

(Senior) Research Technician Immunology, Cell Biology and Pharmacology

Neutrophil extracellular traps (NETs), are part of the innate immune defense mechanisms but become pathogenic when their release is abundant and uncontrolled. Citryll’s lead tACPA (therapeutic anti-citrullinated protein antibody) CIT-013 program interferes with NET formation, function, and clearance downstream of the protein citrullination pathway. Inhibition of NET formation reduces the exposure of autoantigens and toxic histones to the extracellular environment, leading to a decrease of proinflammatory mediators and protection of endothelial lining and organ tissue.

Read More

Latest News

Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board

We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of Citryll. Their impressive and complementary track records in drug discovery and development in pharma, biotech and academia will add significant value…

Read More

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOM Brabant Ventures, BrightGene and ModiQuest contributing…

Read More

Latest News

Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board

We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of Citryll. Their impressive and complementary track records in drug discovery and development in pharma, biotech and academia will add significant value…

Read More

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOM Brabant Ventures, BrightGene and ModiQuest contributing…

Read More

Antibodies clamp down on NET nucleosomes

In the current issue of CMI, Chirivi et al. describe the isolation and characterization of a monoclonal antibody that may find applications in numerous inflammatory conditions. This new antibody, called tACPA, inhibits the completion …

Read More